The effect of neoadjuvant chemotherapy on surgical treatment in patients with esophageal cancer
XU Qingyuan;LI Jingyao;LI Xu;Department of Cardiothoracic Surgery,Southwest Hospital Affiliated to Army Medical University;Department of Anesthesiology,Southwest Hospital Affiliated to Army Medical University;
Objective To explore the effect of neoadjuvant chemotherapy on the short-term and long-term effects of surgical treatment in patients with esophageal cancer. Method Retrospectively analyzed the clinical data of patients with esophageal cancer, who were divided into control group(surgery only) and observation group(underwent paclitaxel plus cisplatin neoadjuvant chemotherapy before surgery), with 50 cases in each group. The postoperative clinical efficacy within 2 weeks after surgery, incidence of adverse reactions and one-year survival rate were compared between the two groups. Result The efficacy of esophageal cancer patients on stage-and-in observation group was better than that in control group(Z=3.059, 2.390; P=0.002, 0.017) and the total efficacy of patients in observation group was better than that in control group(Z=2.116, P=0.034); within observation group, the efficacy of esophageal cancer patients on stage-was better than that of patients on stage-(Z=2.592, P=0.010). The incidence of adverse reactions in observation group was38.0%(19/50), which was higher than that in control group as 18.0%(9/50)(χ2=4.960, P=0.026). Followed-up for one year after surgery, the survival rate in observation group was 92.0%(46/50), and was 84.0%(42/50) in control group. The comparison between the two groups showed no significant difference in the survival rate(χ2=1.559, P=0.212). Conclusion The postoperative efficacy of neoadjuvant chemotherapy before surgery for patients with esophageal cancer is better than that of the surgery alone.
【CateGory Index】： R735.1